Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
On February 11th, STENOCARE A/S (“STENOCARE” or “the Company”) announced that the Company has entered a strategic partnership with Institut des Cannabinoïdes Médicaux Français (“ICMF”) to enter the French market. The partnership is intended to position STENOCARE as a first mover in the French medical cannabis market, which is expected to transition to permanent legalization in 2026. As part of this initiative, STENOCARE and ICMF have submitted a complete regulatory application for STENOCARE’s ASTRUM 10-10 oil to the French medical authorities, within the national framework for assessing medical cannabis products for potential reimbursement. Moreover, Movianto, a subsidiary of Yusen Logistics Healthcare and a major pharmaceutical distribution provider in France, will act as the designated partner overseeing nationwide logistics operations and distribution to pharmacies.
In summary, Analyst Group assesses that STENOCARE’s partnership with ICMF and the submission of a regulatory application for ASTRUM 10-10 in France position the Company well ahead of the expected transition to permanent legalization of medical cannabis in 2026. Early engagement with French authorities, a complete reimbursement-oriented regulatory dossier, and a secured nationwide distribution setup through Movianto are viewed as creating favorable conditions for a first-mover position in a large and attractive market. The differentiated profile of ASTRUM 10-10, offering more consistent and faster absorption, is considered a key driver behind the partnership and remains an important long-term value driver. Although several regulatory steps remain before commercialization can commence, Analyst Group believes that the combination of market size, potential reimbursement status, and early market positioning provides STENOCARE with strong prospects for long-term growth in France.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on STENOCARE. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.